Skip to main content
. 2014 Jul 9;5(15):6267–6279. doi: 10.18632/oncotarget.2195

Figure 5. Silencing of STAT3 increases latency and decreases growth of primary breast tumors.

Figure 5

(A) Graph reports the volume (mm3) of primary tumors derived from injection of 2×106 MDA-MB-231 control (CTR) or STAT3 silenced (sh-STAT3) cells in thoracic mammary fat pads of nude mice (2 MFP/mouse) in 50 μl Matrigel/PBS (1:1). (B) Graph reports the time dependent appearance of primary tumors derived from injection of 2×106 MDA-MB-231 control (CTR) or STAT3 silenced (sh-STAT3) cells in the nude mouse thoracic mammary fat pads (2 MFP/mouse) in 50 μl Matrigel/PBS (1:1). (C) Graph reports the rate of tumor growth, independently from the time of appearance, in mice described in (A). Values are expressed as ratio of the tumor volume over the value of 20 mm3, considered as cut off. The red and the green lines represent the trend of growth of the MDA-MB-231 CTR and sh-STAT3, respectively. (D) Same as in (A), but injecting 2×105 MDA-MB-231 (CTR) or STAT3 silenced (sh-STAT3) cells, in place of 2×106 cells. (E) Same as in (B), but injecting 2×105 cells. (F) Same as in (C), but injecting 2×105 cells. In all graphs, statistical significance was calculated using the Student's t-test. One asterisk (*) indicates a p value ≤ 0.05, two asterisks (**) a p value ≤ 0.01 and three asterisk (***) a p value ≤ 0.005.